ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
CMS Issues Proposed Rule for 2027 Medicare Physician Fee Schedule
On July 14, the Centers for Medicare & Medicaid Services (CMS) released…
HOPPS 2027 Proposed Rule: CMS Proposing Reorganization of Nuclear Medicine APCs
On Thursday, July 2, the Centers for Medicare & Medicaid Services (CMS)…
House Subcommittee Advances Prior Authorization Legislation
The House of Representatives Energy and Commerce Subcommittee on Health has advanced…
